Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient

Fig. 5

Adoptive transfer of CX3CR1-positive T cells to mice bearing RKO tumors over-expressing Fractalkine/CX3CL1. a Weight of RKO-Mock or RKO-CX3CL1 tumors after adoptive transfer of GFP-T cells or CX3CR1-T cells. (b, c) mRNA expression of CD3 and CX3CR1 (human specific primers) from RKO-Mock or RKO-CX3CL1 tumors receiving GFP-T cells or CX3CR1-T cells. d Quantification of Fractalkine in the blood serum of mice bearing RKO-Mock or RKO-CX3CL1 tumors. e Quantification of Fractalkine in the serum of mice bearing NCI-H630 tumors or in non-tumor-bearing mice

Back to article page